Jacobi Capital Management LLC raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 32.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,757 shares of the medical research company’s stock after acquiring an additional 2,396 shares during the quarter. Amgen makes up 0.6% of Jacobi Capital Management LLC’s investment portfolio, making the stock its 28th largest holding. Jacobi Capital Management LLC’s holdings in Amgen were worth $1,762,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Toronto Dominion Bank grew its stake in shares of Amgen by 11.0% in the 3rd quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock valued at $52,066,000 after buying an additional 27,726 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of Amgen by 16.5% in the 3rd quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock valued at $138,115,000 after buying an additional 104,871 shares in the last quarter. Putnam FL Investment Management Co. bought a new stake in shares of Amgen in the 3rd quarter valued at approximately $447,000. Moody Lynn & Lieberson LLC bought a new stake in shares of Amgen in the 3rd quarter valued at approximately $2,353,000. Finally, Patten Group Inc. grew its stake in shares of Amgen by 1,151.5% in the 3rd quarter. Patten Group Inc. now owns 27,859 shares of the medical research company’s stock valued at $389,000 after buying an additional 25,633 shares in the last quarter. 79.50% of the stock is currently owned by institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 4,575 shares of company stock valued at $838,064. Corporate insiders own 0.19% of the company’s stock.
Several brokerages recently commented on AMGN. Argus raised Amgen from a “hold” rating to a “buy” rating and boosted their price target for the company from $192.33 to $220.00 in a research note on Tuesday, January 23rd. Royal Bank of Canada reissued a “hold” rating and issued a $189.00 price target on shares of Amgen in a research note on Wednesday, January 24th. JPMorgan Chase & Co. boosted their price target on Amgen from $184.00 to $189.00 and gave the company a “neutral” rating in a research note on Wednesday, January 24th. Vetr cut Amgen from a “hold” rating to a “sell” rating and set a $181.60 price target for the company. in a research note on Tuesday, March 6th. Finally, BMO Capital Markets boosted their price target on Amgen from $192.00 to $202.00 and gave the company a “market perform” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $191.72.
Amgen, Inc. (NASDAQ AMGN) opened at $182.55 on Tuesday. Amgen, Inc. has a 1-year low of $152.16 and a 1-year high of $201.23. The company has a market capitalization of $135,638.63, a P/E ratio of 71.03, a PEG ratio of 2.31 and a beta of 1.37. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. During the same quarter last year, the firm earned $2.89 earnings per share. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. equities research analysts anticipate that Amgen, Inc. will post 13.25 EPS for the current year.
Amgen declared that its Board of Directors has approved a share repurchase program on Thursday, February 1st that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be issued a dividend of $1.32 per share. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.89%. Amgen’s dividend payout ratio (DPR) is presently 205.45%.
ILLEGAL ACTIVITY WARNING: “Amgen, Inc. (AMGN) Shares Bought by Jacobi Capital Management LLC” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2018/03/20/amgen-inc-amgn-shares-bought-by-jacobi-capital-management-llc.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.